{"filing":{"accession_number":"0001628280-26-055500","cik":"0002023658","ticker":"BCAX","company_name":"Bicara Therapeutics Inc.","form":"8-K","filing_date":"2026-08-11","report_date":"2026-08-11","primary_document":"bcax-20260811.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2023658/000162828026055500/bcax-20260811.htm"},"events":[{"id":26880,"run_id":24448,"accession_number":"0001628280-26-055500","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"The filing discloses Bicara Therapeutics' financial results for Q2 2026 (ended June 30, 2026) via a press release furnished as Exhibit 99.1. The Item 2.02 disclosure includes key financial metrics: cash position of $497.3 million (up from $414.8 million at year-end 2025), R\u0026D expenses of $45.8 million (up from $24.8 million YoY), G\u0026A expenses of $14.2 million (up from $7.2 million YoY), and net loss of $55.4 million (up from $27.4 million YoY). While the filing also announces executive leadership transitions, the primary Item 2.02 disclosure centers on quarterly financial results and cash runway guidance through H1 2029, which is material to investor assessment of the company's financial condition and operational trajectory.","company_name":"Bicara Therapeutics Inc.","ticker":"BCAX","filing_date":"2026-08-11","form":"8-K","submitted_at":null,"items":[{"id":28169,"accession_number":"0001628280-26-055500","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses Bicara Therapeutics' financial results for Q2 2026 (ended June 30, 2026) via a press release furnished as Exhibit 99.1. The Item 2.02 disclosure includes key financial metrics: cash position of $497.3 million (up from $414.8 million at year-end 2025), R\u0026D expenses of $45.8 million (up from $24.8 million YoY), G\u0026A expenses of $14.2 million (up from $7.2 million YoY), and net loss of $55.4 million (up from $27.4 million YoY). While the filing also announces executive leadership transitions, the primary Item 2.02 disclosure centers on quarterly financial results and cash runway guidance through H1 2029, which is material to investor assessment of the company's financial condition and operational trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:38:38.385912+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28169,"accession_number":"0001628280-26-055500","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses Bicara Therapeutics' financial results for Q2 2026 (ended June 30, 2026) via a press release furnished as Exhibit 99.1. The Item 2.02 disclosure includes key financial metrics: cash position of $497.3 million (up from $414.8 million at year-end 2025), R\u0026D expenses of $45.8 million (up from $24.8 million YoY), G\u0026A expenses of $14.2 million (up from $7.2 million YoY), and net loss of $55.4 million (up from $27.4 million YoY). While the filing also announces executive leadership transitions, the primary Item 2.02 disclosure centers on quarterly financial results and cash runway guidance through H1 2029, which is material to investor assessment of the company's financial condition and operational trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:38:38.385912+00:00","company_name":"Bicara Therapeutics Inc.","ticker":"BCAX","filing_date":"2026-08-11"}]}